The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries

<table>Dose-dependent inhibition of EGF-induced ErbB1 activation in U87MG, (a) U87/EGFR (b), and U87/EGFRvIII (c) glioma cells. Serum-starved cells were treated with the indicated concentrations of Iressa ± mechlorethamine (HN2), ZRBA4, or ZR2003 for 2 h followed by a 20 min EGF (50 ng/mL) stimulation. Cell lysates (40 <i>μ</i>g) were fractionated by SDS-PAGE and probed with antiphosphotyrosine (1 : 1000) antibodies (see Materials and Methods for details). Blots were subsequently stripped and reprobed for total ErbB1 (1:1000) followed by <i>α</i>-actinin (1 : 1500). Major protein bands of 170 (ErbB1) and 100 kDa (<i>α</i>-actinin) were obtained.</table>

Journal of Signal Transduction

fig2

Figure 2

Figure 2: The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries 

Figure 2 | The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries 